MannKind (MNKD) Q2 2024 earnings summary

Executive summary

• Achieved ninth consecutive quarter of revenue growth, with Q2 2024 revenue of $72.4M, up 49% year-over-year, and YTD revenue of $139M, up 55%.

• Non-GAAP net income for Q2 2024 was $14.3M, while GAAP net loss was $2M; YTD non-GAAP net income was $29M.

• Cash, cash equivalents, and investments totaled $262M at quarter-end, supporting ongoing investment and liquidity.

• Advanced pipeline with FDA Fast Track for MNKD-101 (Clofazimine Inhalation Suspension), Phase 3 initiation, and ongoing development of MNKD-201 (Nintedanib DPI) and Afrezza pediatric trials.

• Repaid MidCap credit facility and Mann Group convertible note in April 2024, leaving only $230M in senior convertible notes due March 2026.

Financial highlights

• Q2 2024 total revenue was $72.4M, up 49% year-over-year; YTD revenue reached $139M, up 55%.

• Tyvaso DPI royalties were $25.6M in Q2 2024, up 34% year-over-year; Afrezza net revenue grew 20% to $16M.

• Collaboration and services revenue rose 132% year-over-year to $26M, driven by Tyvaso DPI manufacturing for United Therapeutics.

• Gross margin on commercial product sales improved to 73% in Q2 2024 from 72% in Q2 2023.

• Non-GAAP net income for Q2 2024 was $14.3M, or $0.05 per share.

Outlook and guidance

• Expects to meet liquidity needs for at least the next twelve months, supported by strong cash reserves and revenue.

• Key data readouts expected in Q4 2024 for MNKD-201 Phase 1, INHALE-1 (Afrezza pediatric), and full 30-week INHALE-3 data.

• Spray drying capacity for Tyvaso DPI to be fully operational in H1 2025, supporting global expansion.

• Approaching annual revenue run rate of over $275M based on 1H 2024 performance.

• Continued focus on Afrezza growth, international expansion, and pipeline advancement.